Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.48 |
| ▸ | PPARG | P37231 | 13/20 | 0.45 |
| ▸ | PPARD | Q03181 | 13/20 | 0.45 |
| ▸ | PPARA | Q07869 | 12/20 | 0.45 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1690221 | 0.86 | PTGDR2 (0.57) | TSHRHTR2AHTR2CHTR2BPTGDR2 | |
| SCHEMBL1753537 | 0.85 | PTGDR2 (0.67) | TSHRHTR2AHTR2CHTR2BPTGDR2 | |
| SCHEMBL1690305 | 0.84 | PTGDR2 (0.52) | TSHRHTR2AHTR2CHTR2BPTGDR2 | |
| SCHEMBL1753613 | 0.84 | TSHR (0.52) | TSHRHTR2AHTR2CHTR2BPTGDR2 | |
| SCHEMBL1690369 | 0.83 | ABCB11 (0.63) | PTGDR2PPARGPPARDPPARA | |
| SCHEMBL1991361 | 0.83 | TSHR (0.51) | TSHRHTR2AHTR2CHTR2BPTGDR2 | |
| SCHEMBL1753812 | 0.80 | ALDH1A1 (0.53) | TSHRHTR2AHTR2CHTR2BPTGDR2 | |
| SCHEMBL1753809 | 0.78 | MEN1 (0.56) | TSHRPTGDR2 | |
| SCHEMBL5186851 | 0.77 | ABCB11 (0.58) | TSHRHTR2AHTR2CHTR2BPTGDR2 | |
| SCHEMBL2100973 | 0.77 | ABCB11 (0.58) | TSHRHTR2AHTR2CHTR2BPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158820-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-17 | — | — | US | claimed |
| US-20110166117-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | claimed |
| US-20060264435-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | US | claimed |
| US-8158820-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-17 | — | — | US | disclosed |
| US-8158820-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-17 | — | — | US | disclosed |
| US-20110166117-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166117-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166117-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
| US-20060264435-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166117-A1 | Novel Compounds | ADRA2C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR2 | TSHR 2760/4885HTR2A 207/4885HTR2C 119/4885 |
| US-20060264435-A1 | Novel compounds | ADRA2C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR2 | TSHR 2760/4885HTR2A 207/4885HTR2C 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.